Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac N.V (CVAC) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for CureVac N.V (CVAC) over the last 7 years, with Dec 2024 value amounting to $173.3 million.

  • CureVac N.V's Net Income towards Common Stockholders rose 9.27% to -$68.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $211.7 million, marking a year-over-year increase of 171.34%. This contributed to the annual value of $173.3 million for FY2024, which is 161.91% up from last year.
  • According to the latest figures from FY2024, CureVac N.V's Net Income towards Common Stockholders is $173.3 million, which was up 161.91% from -$279.9 million recorded in FY2023.
  • CureVac N.V's Net Income towards Common Stockholders' 5-year high stood at $173.3 million during FY2024, with a 5-year trough of -$471.0 million in FY2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$254.1 million (2022), whereas its average is -$120.2 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 205.94% in 2021, then skyrocketed by 161.91% in 2024.
  • Over the past 5 years, CureVac N.V's Net Income towards Common Stockholders (Yearly) stood at -$154.0 million in 2020, then plummeted by 205.94% to -$471.0 million in 2021, then spiked by 46.06% to -$254.1 million in 2022, then decreased by 10.18% to -$279.9 million in 2023, then surged by 161.91% to $173.3 million in 2024.